ASSESSMENT OF BLOOD MARKERS AFTER RADIONUCLIDE THERAPY FOR OSTEOGENIC METASTASIS OF KIDNEY AND PROSTATE CANCER . Wor.Bul.Pub.Helt. 2022;12:66-69. Accessed February 3, 2026. https://scholarexpress.net/index.php/wbph/article/view/1135